United States Patent 12,396,986 (Combination Dry Powder Inhaler): Scope of Claims, Claim Construction Risk, and US Patent Landscape
Patent US 12,396,986 claims a once-daily dry powder inhalation combination product in which Compound (I) is a specific “azoniabicyclo” quaternary ammonium/cationic compound administered at ~62.5 mcg/dose as a pharmaceutically acceptable anion salt, and Compound (II) is a specific phenolic compound (with the named chiral substituent “(1R)”) administered at ~25 mcg/dose. The claims also tightly constrain formulation engineering (dry powder, lactose carrier, magnesium stearate ternary agent, unit-dose device formats) and optionally add fluticasone furoate (100 mcg/dose) as a third active.
High-level scope: the claim set is not just a “two-API combo.” It is a device-agnostic but formulation-constrained claim set targeting the exact dose ratio, polymorph/dry-powder presentation conceptually, and excipient/ternary-agent performance design, with multiple paths to infringement based on either admixture or separate blister/capsule/cartridge unit doses.
Practical exclusivity reality: protection is strongest against (i) US dry powder inhaler products using the same actives and dose amounts, (ii) products using the claimed salt choices for Compound (I) (claim 2/23/32/42/43/44/45/46/47), and (iii) products employing lactose + magnesium stearate as the ternary agent in the stated % w/w ranges for each composition.
What does US patent 12,396,986 claim: compound identities, doses, salt forms, and inhalation regimen?
Core combination required by claim 1
Claim 1 requires a combination product with:
- Compound (I): “a compound of the formula” where X− is a pharmaceutically acceptable anion, with Compound (I) present at about 62.5 mcg/dose, in the form of a dry powder.
- Compound (II): specifically identified as
4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a pharmaceutically acceptable salt, with Compound (II) present at about 25 mcg/dose, in the form of a dry powder.
- Once-daily administration.
- Simultaneous administration, with compounds (a) and (b) presented in a form “adapted for simultaneous administration.”
- The product is framed for dry powder inhalation later in dependent claims.
This is a two-API inhalation regimen claim with dose-anchored actives and presentation constraints.
Salt-limited scope for Compound (I) (dependent claim set)
Claim 2 defines X− selection as a list of common pharmaceutically acceptable anions. Claim 23/32 repeat the structure with lists; claim 24/33 lock to bromide.
Key named salt list (Claim 2 / 23 / 32):
- chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate, p-toluenesulfonate.
Key narrowed embodiments:
- Compound (I) is bromide (Claim 3 via Claim 3/24?; explicitly Claim 24 and Claim 33).
Compound (II) salt identity also constrained
Dependent claim 4 specifies Compound (II) as the triphenylacetate salt:
- Compound (II) triphenylacetate is explicitly required in Claim 4 and again in Claim 5/26/25/34/35.
Hard dose ratio and hard “dry powder” requirement
- ~62.5 mcg/dose (Compound I)
- ~25 mcg/dose (Compound II)
- Both stated “in the form of a dry powder.”
That means a competitor designing a different dose (even if same actives), different exposure schedule (twice daily), or non-dry-powder presentations (e.g., nebulized solution, pressurized MDI) can potentially avoid the literal combination claims.
Which formulations and inhaler device formats are covered by US 12,396,986?
Inhalation via dry powder medicament dispenser
Claim 6 restricts the claim to a product “suitable for administration by inhalation via a medicament dispenser,” listing:
- reservoir dry powder inhaler
- unit-dose dry powder inhaler
- pre-metered multi-dose dry powder inhaler
This does not require one specific device platform; it captures the major dry powder architecture categories.
Separate vs admixed dry powder compositions
Claim 7 covers two architectures:
- separate dry powder compositions for Compound (I) and Compound (II), or
- an admixed dry powder composition containing both.
Carrier and ternary agent constraints
Claim 8 sets carrier = lactose.
Claim 9 requires the composition contains a “ternary agent.”
Claim 10 specifies ternary agent = magnesium stearate.
This is a critical formulation locking point: it is not enough to have magnesium stearate somewhere in the overall product; the claims require it as a ternary agent in the dry powder composition.
Unit dose container types
Claim 11 limits unit dose forms to:
- capsule
- cartridge
- blister
Claim 38/56 repeats this for unit dose forms of both compositions.
Quantitative ternary agent loading
Claim 42-47 specify magnesium stearate % w/w by composition:
- 0.6% w/w for Compound (I) composition
- 1.0% w/w for Compound (II) composition
- Claim 44 makes both specific simultaneously.
Claim 55 and related later claims repeat that the magnesium stearate in Compound (II) composition is ~1.0% w/w.
Admixture allowance while keeping excipient requirements
The excipient requirements apply regardless of whether the API powders are separate or admixed (claims 7-10 and downstream constraints). A design that mixes APIs but changes excipient identity or ternary agent composition likely aims to avoid dependent claim coverage.
How broad are the optional fluticasone furoate claims (triple therapy coverage)?
Addition of fluticasone furoate (claims 12–15; 14–15; 27–30; 31)
Claim 12 adds:
- fluticasone furoate as a further component.
Claim 13 specifies:
- fluticasone furoate present at about 100 mcg/dose.
Claims 14–15 repeat the same pattern with narrower dependency.
Later structural claim 31 expands to a defined two-component API split (Compound I/II) plus:
- fluticasone furoate as part of the second composition at about 100 mcg/dose.
How this changes infringement pathways
A competitor offering a two-API bronchodilator formulation could avoid trios if they omit fluticasone furoate. Conversely, a triple-therapy dry powder inhaler using the same actives and dose levels may fall into the “further comprises fluticasone furoate” branches.
Claim chart style breakdown: what is actually litigatable (independent vs dependent levers)?
Independent claim set
- Claim 1: broadest formulation and dose anchored, includes once daily + simultaneous administration + dry powder.
- Claim 22: formulation-defined dual composition with explicit % magnesium stearate per composition and lactose.
- Claim 31: formulation-defined with first and second dry powder compositions with explicit inclusion of fluticasone furoate in the second composition.
Dependent claims that narrow the infringement surface
- Salt selection for Compound (I): Claim 2, 3, 23, 24, 32, 33.
- Compound (II) salt identity: Claim 4, 5, 25, 26, 34, 35.
- Device categories: Claim 6, 16, 37, 40, 50.
- Separate vs admixed powder architecture: Claim 7, 17, 51.
- Lactose carrier: Claim 8, 18, 52.
- Ternary agent presence and identity: Claim 9-10, 19-20, 53-54.
- Unit-dose packaging forms: Claim 11, 21, 38, 41, 56.
- Mg stearate % w/w: Claim 42-47, 55.
- Optional fluticasone furoate addition and dose: Claim 12-15, 27-30, 48-49, 31.
Litigation reality: even if a defendant avoids Claim 1 by dose or regimen, plaintiffs can often plead dependent-claim infringement where the accused product maps to salt identity and excipient loading.
What are the strongest “design-around” levers implied by the claim scope?
1) Changing the dose away from ~62.5 mcg/dose and ~25 mcg/dose
Claim language is anchored to “about” but is still numerically specific. A product with materially different actives’ dose per day is a direct avoidance vector.
2) Changing Compound (I) anion salt
The salt list in Claim 2 is finite. A defendant could target an anion outside the list, or use a different salt form that does not map to the claimed “X− is” list.
3) Changing Compound (II) salt form
Claim 4/5/25/26/34/35 specify triphenylacetate.
If the marketed Compound (II) is a different salt, the defendant can reduce dependent claim overlap.
4) Changing excipient system or ternary agent
The claims strongly lock:
- lactose carrier
- magnesium stearate as ternary agent
- sometimes mg stearate % w/w
Replacing magnesium stearate with another ternary agent and/or changing loading is a high-probability design-around.
5) Avoiding the dry powder inhaler architecture
Claims 6/16/37/40/50 require inhalation via dry powder dispenser categories. Non-inhalation routes or different inhaler mechanics not matching the definitions can avoid dependent coverage.
6) Avoiding fluticasone furoate when targeting only two-API therapy
Tri-therapy branches require fluticasone furoate at ~100 mcg/dose.
US patent landscape: what other patents likely surround this claim set (scope adjacency map)
Because the question is specifically about US 12,396,986 and only provides the claim text, the landscape below is scoped to the claim-based adjacency domains that typically cluster around such a family: active ingredient salts, combination dose regimens, dry powder inhaler formulations with lactose/magnesium stearate, and triple therapy inhalation compositions.
Adjacency buckets to search in US/EP for freedom-to-operate
- Compound (I) salt patents
- specific anion selections (including bromide)
- preparation and particle engineering (if claimed elsewhere)
- Compound (II) salt patents
- triphenylacetate vs alternative salts
- Combination-specific patents
- simultaneous delivery and once-daily regimen claims
- compatibility/stability claims for combination powders
- Inhalation formulation patents
- lactose blending
- magnesium stearate as ternary agent
- unit-dose content uniformity and inhaler performance indices
- Device-adaptation patents
- reservoir vs pre-metered vs unit-dose dry powder inhalers
- Triple therapy formulation patents
- fluticasone furoate integration with the two bronchodilator actives
- exact dosing matching (100 mcg/dose)
How this claim set functions inside a typical portfolio
This claim set looks like an “end-stage” formulation/combination IP layer that may sit after:
- API synthesis and salt formation claims, and
- earlier combination selection claims,
and before later “specific inhaler performance” or “manufacturing method” claims.
Orange Book status and FDA exclusivity: what it implies for US 12,396,986 risk timing
The claim set is for an inhalation combination product at fixed microgram doses, which typically maps to an NDA/505(b)(2) product and would appear in the Orange Book if it is tied to an approved drug product.
However, no Orange Book listing, FDA application number, or listed patent-to-drug link is provided here, so no timing can be asserted from the record.
Where could generic entry risks concentrate given this claim structure?
Paragraph IV / ANDA risk tends to be formulation-level
For a dry powder inhaler with fixed microgram actives, the biggest ANDA/505(b)(2) design-around targets are:
- salt form selection
- excipient and ternary-agent identity
- dose per unit
- presentation architecture (separate vs admixed)
- inhaler compatibility category
If a competitor files for a “different inhaler” but same powder
Dependent claim coverage does not require a specific device brand, only categories. A generic entrant would have to ensure the accused formulation does not use lactose + magnesium stearate ternary agent (or does not meet the exact mg stearate % w/w limits where pleaded).
If the competitor omits Compound (II) salt identity
If Compound (II) is not triphenylacetate, claims that require triphenylacetate (4/5/25/26/34/35) would not read.
But claim 1/22/31 still protect Compound (II) as “Compound (II) or pharmaceutically acceptable salt thereof,” unless the asserted count is limited to triphenylacetate-dependent claims.
Key Takeaways
- US 12,396,986 is a dose-anchored, dry powder, once-daily, simultaneous administration combination claim for Compound (I) ~62.5 mcg/dose and Compound (II) ~25 mcg/dose.
- Dependent claims narrow to Compound (I) anion lists and explicitly bromide, and narrow Compound (II) to triphenylacetate in multiple embodiments.
- Formulation scope is tightly constrained to lactose carrier and magnesium stearate as ternary agent, with explicit 0.6% w/w for Compound (I) and 1.0% w/w for Compound (II) powders in the defined separate composition embodiments.
- The device language covers major dry powder inhaler architecture categories, while also narrowing to capsule/cartridge/blister unit doses.
- A triple-therapy branch adds fluticasone furoate at ~100 mcg/dose, integrating it into the combination product in dependent claims including a defined two-composition split.
FAQs
-
What design changes most directly avoid US 12,396,986 dependent claims?
Avoiding the claimed anion salt list for Compound (I), using non-triphenylacetate Compound (II salt (where the dependent claims require it), and replacing lactose + magnesium stearate ternary agent architecture, especially the 0.6%/1.0% w/w ranges.
-
Does the patent cover both admixed and separate dry powder compositions?
Yes. It covers both separate compositions and an admixed dry powder presentation, with lactose carrier and magnesium stearate ternary-agent constraints.
-
Is fluticasone furoate mandatory to infringe?
No. Fluticasone appears in dependent “further comprises” claims and in the defined triple-therapy independent claim (Claim 31). Two-API products can still infringe without fluticasone if they meet earlier claim elements.
-
Which unit-dose forms are specified for dry powder administration?
Capsules, cartridges, and blisters (including separate unit dose forms for each composition).
-
What is the key combination dosing ratio the claims hardcode?
~62.5 mcg/dose for Compound (I) paired with ~25 mcg/dose for Compound (II), both in dry powder and for once-daily simultaneous administration.
References
No external documents were provided or cited in the prompt.
